Grace Therapeutics (GRCE) Profit After Tax (2019 - 2026)
Grace Therapeutics (GRCE) posted Profit After Tax of -$1.2 million for Q1 2026, up 49.11% sequentially from -$2.3 million in Q4 2025, and down 285.22% YoY from $636000.0 in Q1 2025.
Grace Therapeutics (GRCE) Profit After Tax (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Profit After Tax for 8 years, with the latest figure at -$1.2 million in Q1 2026.
- Quarterly Profit After Tax fell 285.22% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.8 million (up 18.55% YoY) and the FY2026 annual result came in at -$7.8 million, up 18.55% from the prior year.
- Profit After Tax advanced to -$1.2 million in Q1 2026 per GRCE's latest filing, from -$2.3 million in the prior quarter.
- Over five years, Profit After Tax peaked at $636000.0 in Q1 2025 and troughed at -$29.1 million in Q1 2023.
- A 5-year average of -$4.7 million and a median of -$3.4 million in 2025 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax sank 602.45% in 2022, then soared 120.09% in 2025.
- Over 5 years, Profit After Tax stood at -$3.9 million in 2022, then soared by 38.52% to -$2.4 million in 2023, then sank by 73.78% to -$4.2 million in 2024, then surged by 44.28% to -$2.3 million in 2025, then jumped by 49.11% to -$1.2 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$1.2 million, -$2.3 million, and -$938000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | -15.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.79 Mn |
| Mar 31, 2026 | -1.18 Mn |
| Dec 31, 2025 | -2.32 Mn |
| Sep 30, 2025 | -938,000.00 |
| Jun 30, 2025 | -3.36 Mn |
| Mar 31, 2025 | 636,000.00 |
| Dec 31, 2024 | -4.16 Mn |
| Sep 30, 2024 | -3.43 Mn |
| Jun 30, 2024 | -2.62 Mn |
| Mar 31, 2024 | -3.17 Mn |
| Dec 31, 2023 | -2.39 Mn |
| Sep 30, 2023 | -3.27 Mn |
| Jun 30, 2023 | -4.02 Mn |
| Mar 31, 2023 | -29.09 Mn |
| Dec 31, 2022 | -3.89 Mn |
| Sep 30, 2022 | -4.93 Mn |
| Jun 30, 2022 | -4.52 Mn |
| Mar 31, 2022 | -7.82 Mn |
| Dec 31, 2021 | -3.78 Mn |
| Sep 30, 2021 | 981,000.00 |